Hier bekommt man den Marktführer in diesem Bereich aktuell zu einem extrem günstigen Preis.
Ich werde heute mit einer kleinen Position einsteigen.
Research and Markets - Global Proton Therapy Market - Forecast to 2022
Key Vendors are Elekta, IBA & Varian Medical Systems
DUBLIN, May 05, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Proton Therapy Market & Forecast (12 Countries Market Data), Patients Treated at Proton Therapy Centers, Reimbursement Policies" report to their offering.
Global Proton Therapy Market potential is more than US$ 50 Billion in 2016. The proton therapy market is expected to grow with double digit CAGR in future.
United States dominates the Proton Therapy Market globally, but it is losing its proton therapy market share year on year.
Japan has the second highest proton therapy market share worldwide, but its proton therapy market is increasing year on year.
Europe proton therapy market possesses a potential of more than US$ 10 Billion. In the case of Europe, France used to have the biggest proton therapy market share for the year 2009. But by the end of year 2012, Germany dethroned France from its peak place and took its spot.
However as per our research United Kingdom proton therapy market will remove Germany proton therapy market form top position in future.
Russia will be the one country which will be interesting to watch as it will increase its market share thrice in a span of 4 years.
Asia proton therapy market is forecasted to grow with 18 percent CAGR.
Proton therapy market is dominated by Japan, but China proton therapy market share is rising rapidly. Korea is also increasing its proton therapy market year on year.
Rising cancer incidence worldwide is the major key driver to boost proton therapy market.
Varian Medical Systems
For more information about this report visit www.researchandmarkets.com/research/gzwgmt/global_proton
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
kaum dabei schon gibt's gute Nachrichten
Strategic review of IBA Dosimetry business
Louvain-la-Neuve, Belgium, July 20, 2018 - IBA (Ion Beam Applications S.A., EURONEXT), the worlds leading provider of solutions for the diagnosis and treatment of cancer, today announces a strategic review of its Dosimetry business. The company is reviewing strategic alternatives for IBA Dosimetry, including a sale, merger, initial public offering, or retention of the business, and will provide an update on its plans by the end of the year.
Olivier Legrain, Chief Executive Officer of IBA, commented: IBA Dosimetry saw strong growth in 2017. We are pleased that this growth now enables IBA to explore options to maximize the future value and strategic potential of this business. This review is in line with our stated aim to focus on our core proton therapy and other accelerators business and invest in technology, most specifically software. This will enable the company to further capitalize on the growth prospects and build on its market leading position in the global proton therapy market.
Die Aufträge sind da.... fehlt nur noch der Kurs :-)